Individualized immunosuppression in virus-negative inflammatory cardiomyopathy

Andrea Frustaci^{1

2}, Matteo A Russo³, Cristina Chimenti¹

Affiliations

¹ Department of Clinical, Internal, Anesthesiologist and Cardiovascular Sciences, La Sapienza University, Viale del Policlinico 155, 00161 Rome, Italy.
² Cellular and Molecular Cardiology Lab, IRCCS L. Spallanzani, 00149 Rome, Italy.
³ MEBIC Consortium, San Raffaele Open University and IRCCS San Raffaele, 00166 Rome, Italy.

Editorial

Andrea Frustaci et al. Eur Heart J. 2022.

. 2022 Dec 1;43(45):4760.

doi: 10.1093/eurheartj/ehac559.

Andrea Frustaci^{1

2}, Matteo A Russo³, Cristina Chimenti¹

¹ Department of Clinical, Internal, Anesthesiologist and Cardiovascular Sciences, La Sapienza University, Viale del Policlinico 155, 00161 Rome, Italy.
² Cellular and Molecular Cardiology Lab, IRCCS L. Spallanzani, 00149 Rome, Italy.
³ MEBIC Consortium, San Raffaele Open University and IRCCS San Raffaele, 00166 Rome, Italy.

No abstract available

Conflict of interest statement

Conflict of interest: None declared

Immunosuppressive therapy in virus-negative inflammatory cardiomyopathy: 20-year follow-up of the TIMIC trial.
Chimenti C, Russo MA, Frustaci A. Chimenti C, et al. Eur Heart J. 2022 Sep 21;43(36):3463-3473. doi: 10.1093/eurheartj/ehac348. Eur Heart J. 2022. PMID: 35831932 Free PMC article. Clinical Trial.
Immunosuppressive therapy of myocarditis and inflammatory cardiomyopathy in the light of new data.
Ozieranski K, Tyminska A, Caforio ALP. Ozieranski K, et al. Eur Heart J. 2022 Dec 1;43(45):4758-4759. doi: 10.1093/eurheartj/ehac500. Eur Heart J. 2022. PMID: 36263783 No abstract available.